Compare Biogen Inc (BIIB) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs SAP SE — how do they compare? Biogen Inc trades at $193.67 (market cap $28.34B), while SAP SE trades at $158.83 (market cap $181.79B). The key difference: SAP SE is far larger — about 6.4× Biogen Inc's market cap, and SAP SE pays a 1.89% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | SAP | |
|---|---|---|
Market Cap | $28.34B | $181.79B |
Sector | Health | Technology |
52-Week High | $216.63 | $308.61 |
52-Week Low | $122.68 | $148.06 |
Enterprise Value | $30.62B | $179.30B |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
SAP trades at $159.97, up 1.34% today, with a neutral technical signal and strong profitability metrics including a 19.58% net income margin. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $2. Recent news highlights SAP's resolution of EU antitrust concerns and strategic focus on AI investments to drive cloud growth, which now represents over 60% of revenue.
SAP presents a compelling investment case with robust fundamentals and analyst consensus pointing to significant upside, but faces risks from competitive pressures and execution challenges in its AI transition. The stock's current valuation below consensus price targets suggests potential for appreciation if cloud and AI initiatives deliver expected growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
